Inflammatory Breast Cancer
29
2
8
15
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
6.9%
2 terminated out of 29 trials
88.2%
+1.7% vs benchmark
21%
6 trials in Phase 3/4
47%
7 of 15 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 15 completed trials
Clinical Trials (29)
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
Onvansertib + Paclitaxel In TNBC
A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer
Refining Local-Regional Therapy for IBC
A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer
Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer
Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Conserving Surgery in Inflammatory Breast Cancer After Neoadjuvant Chemotherapy
Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients
Accelerated Radiation Therapy After Surgery in Treating Patients With Breast Cancer
Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer
Denosumab as an add-on Neoadjuvant Treatment (GeparX)
Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto)
Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy
Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer
MUC1 Vaccine for Triple-negative Breast Cancer
A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)
Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer